Skip to main content

Table 3 Linear mixed-effect models for change in FVC over time

From: A formula for predicting emphysema extent in combined idiopathic pulmonary fibrosis and emphysema

 

Clinical trial cohort (N = 455)

Real-world cohort* (N = 124)

Relative FVC change (%)

Absolute FVC change (L)

Relative FVC change (%)

Absolute FVC change (L)

Coefficient

P-value

Coefficient

P-value

Coefficient

P-value

Coefficient

P-value

Model A

 CPFE formula

0.0646

< 0.0001

0.0012

0.2445

0.0025

0.3708

0.0048

0.3686

 Months

–0.1143

< 0.0001

–0.0030

< 0.0001

–0.0042

< 0.0001

–0.0108

0.0000

Model B

 CPFE formula

0.0362

0.2564

0.0009

0.2934

0.0007

0.7964

0.0020

0.7061

 Months

–0.1087

< 0.0001

–0.0026

< 0.0001

–0.0042

< 0.0001

–0.0108

0.0000

 ILD extent

–0.0533

0.0012

–0.0013

0.0016

0.0045

0.0221

0.0064

0.0781

 Male

–0.4328

0.3787

–0.0203

0.1111

–0.1087

0.0583

–0.1681

0.1121

 Age

0.0312

0.2410

0.0009

0.2115

0.0058

0.0112

0.0145

0.0005

 Current/former smoker

0.3737

0.4488

0.0093

0.4627

0.0935

0.0340

0.1134

0.1652

Model C

 CPFE formula

0.0841

0.3546

0.0025

0.2832

–0.0214

0.0259

–0.0333

0.0649

 Months

–0.1085

< 0.0001

–0.0026

< 0.0001

–0.0042

< 0.0001

–0.0108

0.0000

 ILD extent

–0.0425

0.0920

–0.0010

0.1370

0.0004

0.8762

–0.0001

0.9858

 Male

–0.4327

0.3791

–0.0203

0.1114

–0.1099

0.0501

–0.1696

0.1033

 Age

0.0310

0.2440

0.0009

0.2150

0.0062

0.0055

0.0152

0.0002

 Current/former smoker

0.3861

0.4340

0.0098

0.4423

0.0907

0.0354

0.1084

0.1778

 CPFE formula x ILD extent

–0.0012

0.5732

0.0000

0.4514

0.0009

0.0161

0.0015

0.0412

  1. Linear mixed-effects models for relative (%) and absolute (L) change from baseline in FVC over 48 weeks in the clinical trial cohort and all available data* for the real-world cohort for patients with IPF, with and without emphysema
  2. CPFE combined pulmonary fibrosis and emphysema; FVC forced vital capacity; ILD interstitial lung disease; IPF idiopathic pulmonary fibrosis
  3. * Mean follow-up time of 18.8 months
  4. Time elapsed from baseline lung-function tests